The Use of Chromatography to Manufacture Purer and Safer Plasma Products

Biotechnology and Genetic Engineering Reviews

Volumn 17, Issue 1, 2000, Pages 37-70

  Johnston, Anna ^a   Adcock, Wayne ^a  

^a CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATOGRAPHY; MANUFACTURE; SAFETY FACTOR; VIRUSES;

ANTITHROMBIN III; FACTOR VIII; MANUFACTURING PROCESS; PLASMA PRODUCTS; PURIFICATION TECHNIQUES;

AGGREGATES;

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRIN GLUE; FIBRINOGEN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; PROTHROMBIN COMPLEX; THROMBIN;

AFFINITY CHROMATOGRAPHY; BLOOD TRANSFUSION; CHROMATOGRAPHY; FRACTIONATION; GEL FILTRATION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; PURIFICATION; REVIEW;

EID: 0034488375     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2000.10647987     Document Type: Article

References (153)

1. Adamson, S., Charlebois, T., O'Connell, B. and Foster, W. (1998). Viral safety of recombinant factor IX. Seminar in Hematology 35, 22-27
2. Adcock, W. (1998). Chromatographic partitioning and heat inactivation of viruses during the manufacture of plasma derivatives. Ph, D. Thesis. Melbourne, Australia: Melbourne University
3. Adcock, W. L., Macgregor, A., Davies, J. R., Hatparki, M., Anderson, D. A. and Goss, N. H. (1998a). Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin. Biotechnology and Applied Biochemistry 28, 85-94
4. Adcock, W. L., Macgregor, A., Davies, J. R., Hattarki, M., Anderson, D. A. and Goss, N. H. (1998b). Chromatographic removal and heat inactivation of hepatitis B virus during manufacture of human albumin. Biotechnology and Applied Biochemistry 28, 169-178
5. Adcock, W., Hattarki, M., Broumis, C., Macgregor, A., Johnston, A., Uren, E. and Goss, N. H. (1999). Chromatographic partitioning of model and relevant blood borne viruses and of immune complexes of relevant viruses in the manufacture of albumin and immunoglobulin. Presented at Plasma Product Biotechnology Meeting, March 1999 Queensland, Australia
6. Andersson, I., Connor, S. E., Lindquist, L. O. and Watson, E. A. (1996). Validation study for the removal/inactivation ol viruses during a chromatographic purification process for albumin and IgG. Abstract presented at 24th Conference International Society of Blood Transfusion, April, Japan
7. Andersson, L. O., Borg, H. and Miller-Andersson, M. (1975). Purification and characterization of human factor IX. Thrombosis Research 7, 451-459
8. Barandun, S. and Isi-Iker, H. (1986). Development of immunoglobulin preparations for intravenous use. Vox Sanguinis 51, 157-60
9. Barker, L. F. and Hoofnagle, J. H. (1974). Transmission of viral hepatitis, type B, by plasma derivatives. Developments in Biological Standardization 27, 178-188
10. Barrett, N., Polser, G., Eibl, J. and Dorner, F. (1994). Inactivation and partitioning of HIV-1 and model viruses during the manufacture of Immunine and Immunate. Abstract at XXI International Congress of World Hemophilia, Mexico, 1994
11. Bees, W. C. H., Friesen, A. D. and Janzen, R. G. (1989). Validation of a large scale column chromatographic process for production of albumin and intravenous immune globulin. In: Purification, clinical and biological applications. Fractionation and Applications. Eds J. -F. Stoltz and C. Rivât. Colloque INSERM 175, 207-216
12. Berglof, J. H. and Eriksson, S. E. (1984). Improvements in the chromatographic preparation of human Immunoglobullin. Presented at the 18th Congress of the International Society of Blood Transfusion, Munich, 1984
13. Berglof, J. H., Andersson, I., Lees, G. M. and Darling, A. J. (1992). Validation of chromatographic procedures used in fractionation of plasma derivatives. In: Virologicai Safety Aspects of Plasma Derivatives. Cannes, France: IABS
14. Bertolini, J., Davies, J. R., Wu, J. and Coppola, G. (1998). Purification Of Immunoglobulins. Au 97/00498
15. Biescas, H., Gensana, Ml, Fernendez, J., Ristol, P., Massot, M. and Watson, E. (1998). Characterisation and viral safety validation study of antithrombin III obtained through affinity chromatography. Haematologica 83, 305-315
16. Bhikenmeier, G. and Kopperschlager, G. (1989). Application of dyes in serum protein separation. In: Biotechnology of Plasma Proteins: Fractionation and Applications. Eds, J. -F. Stoltz and C. Rivat. Colloque INSERM 175, 217-228
17. Björling, H. (1985). A new protein fractionation method using ion-exchange chromatography and PEG precipitation. Vox Sanguinis 49, 240-243
18. Bresee, J. S., Mast, E. E., Coleman, P. J., Baron, M. J., Schonberger, L. B., Alter, M. J., Jonas, M. M., Yu, M. U., Renzi, P. M. and Schneider, L. C. (1996). Hepatitis C virus infection associated with administration of intravenous immune globulin. Journal of the American Medical Association 276, 1563-1567
19. Brock, T. D. (1983). Assays of viruses in water. In: Membrane Filtration. Ed, D. Brock Thomas, Chap. 12, pp 272-282. New York: Science Tech. Inc, Springer-Verlag
20. Burnouf, T. (1991). Integration of chromatography with traditional plasma protein fractionation methods. Bioseparation 1, 383-396
21. Burnouf, T. (1993). Chromatographic removal of viruses from plasma derivatives. In: Virologicai safety aspects of plasma derivatives. Developments in Biological Standardization 81, 199-209
22. Burnouf, T. (1995). Chromatography in plasma fractionation: benefits and future trends. Journal of Chromatography B 664, 3-15
23. Burnouf, T., Constans, J., Clerc, A., Descamps, J., Martinache, L. and Goudemand, M. (1987). Large scale chromatographic purification of alpha-1-antitrypsin from human plasma supernatant 11+III. Developments in Biological Standardization 67, 31-38
24. Burnouf, T., Burnouf-Radosevich, M., Huart, J. J. and Goudemand, M. (1991). A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sanguinis 60, 8-15
25. Burnouf-Radosevich, M. and Burnouf, T. (1992). Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vav Sanguinis 62, 1-11
26. Burnouf-Radosevich, M., Burnouf, T. and Huart, J. J. (1990). Biochemical and physical properties of a solvent-detergent-treated fibrin glue. Vox Sanguinis 58, 77-84
27. Burnouf-Radosevich, M., Appourchaux, P., Huart, J. J. and Burnouf, T. (1994). Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sanguinis 67, 132-138
28. Cameron, R., Davies, J. R., Adcock, W., Macgregor, A., Barford, J. P., Cossart, Y. and Harbour, C. (1997). The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures. Biologicals 25, 391-401
29. Chen, S. X., Hammond, D. J., Klos, A. M., Wood, W. D., Wydick, J. E. and Lebing, W. R. (1998). Chromatographic purification of human alpha 1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste. Journal of Chromatography A 800, 207-218
30. Chudzso, T. and Inglot, A. D. (1973). Chromatographic purification of the Sindbis virus: Comparison of different methods. Archivum Imnnmologiae et Tlierapiae Experimentalis 21 227-237
31. Coan, M. H., Brockway, WJ., Eguizabal, H., Krieg, T. and Fournel, M. (1985). Preparation and properties of alpha I-proteinase inhibitor concentrate from human plasma. Vox Sanguinis 48, 333-342
32. Cohn, E. J., Strong, L. E., Hughes, W. L., Mulford, D. J., Ashworth, J. N., Melin, M. and Taylor, H. L. (1946), Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. Journal of the American Chemical Society 62, 459-475
33. Condie R. M. (1979). A preparation of Intravenous human and animal gamma globulins and isolation of albumin (US Patent 4136094)
34. CPMP. Committee For Proprietary Medicinal Products. (1995). Revised CPMP guidelines on virus validation studies. CPMP/268/95, pp 1-24 (report). U. K. –London
35. Creveld, S., VAN Pascha, C. N. and VEDER, H. A. (1961). The separation of AHF from nbnnogen. HI. Thrombosis et Diathesis Haemorrhagica 6, 282-286
36. Curling, J. M. (1980). Albumin purification by ion exchange chromatography. In: Methods of Plasma Protein Fractionation. Ed, J. M. Curling, pp 71-91. London, U. K.: Academic Press
37. Curran, J. W., Lawrence, D. N., Jaffe, H., Kaplan, J. E., Zyla, L. D., Chamberland, M., Einstein, R., Lui, K., Schonberger, L. B., Spira, T. J., Alexander, W. J., Swinger, G., Ammann, A., Solomon, S., Auerbach, D., Mildvan, D., Stoneburner, R., Jason J. M., Haverkos, H. W. and Evatt, B. L. (1984). Acquired immunodeficiency syndrome (AIDS) associated with transfusions. New England Journal of Medicine 310, 69-75
38. Cuthbertson B., Reid, K. G. and Foster, P. R. (1991). Viral contamination of human plasma and procedures for preventing virus transmission by plasma products. Blood separation and plasma fractionation, pp 385-435. New York: Wiley-Liss, Inc
39. Dam, J., Barington, K. A. and Kaersgaard, P. (1999). Plasma Fractionation based on chromatography and precipitation by polyethylene giycol and capryjic acid. Abstract 30th Plasma Product Biotechnology Meeting, March 1999, Queensland, Australia
40. DAMEVSKA, O. T., IVANOVSKI, D., KOLEVSKI, D. and STEFANOVSKA, V. (1999). Albumin production by chromatography and clinical use. Abstract 804. Plasma Product Biotech-nology Meeting, March 1999, Queensland, Australia
41. Dengler, T., Stocker, U., Kellner, S. and Forst, G. (1990). Large scale gel filtration chromatography for the production of a solvent detergent - treated high-purity factor VIII concentrate. Vox Sanguinis 58, 257-263
42. Denson, K. W. (1969). Coagulant and anticoagulant action of snake venoms. Toxicon 7, 5-11
43. Dike, G. W. R., Bidwell, E. and Rizza, C. R. (1972). The preparation and clinicai use of a new concentrate containing factor IX, prothrombin and factor X and a separate concentrate containing factor VII. British Journal of Haematology 22, 175-201
44. Downing, L. A., Bernstein, J. M. and Walter, A. (1992). Active respiratoiy syncytial virus punned by ion-exchange chromatography: characterization of binding and elution requirements. Journal of Virological Methods 38, 215-228
45. Eibal, J., Kaeser, A., Heimburger, N., Karges, H. E., Horowitz, B., Lundbald J. L., Mozen, M. M., Mannucci, P. M., Mortini, M., Morgenthaler, J. J., Piszkiewicz D. and Stephan, W. (1988). Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages Vox Sanguinis 54, 228-245
46. Einarsson, M., Kaplan, L. and Utter, G. P. (1978). Purification of hepatitis B surface antigen by affinity chromatography. Vox Sanguinis 35, 224-233
47. EINARSSON, M., KAPLAN, L. and PERTOFT, H. (1981). A two step Procedure for the Purification _ of hepatitis B surface antigen. Vox Sanguinis 41, 91-97
48. EPFA (European Plasma Fractionation Association) Working Group On Quality Assurance. (1995). Points To Consider In Validation Of Virus Inactivation. January 1995
49. Esmon, C. T., Owen, W. G. and Jackson, C. M. (1974). A plausible mechanism for pro-hrombin activation by factor Xa, factor Va, phospholipid, and calcium ions. Journal of Biological Chemistry 249, 8045-8047
50. Feldman, F., Chandra, S. and Huang, C. (1995), Improved safety from plasma derivatives: purification and Viral elimination characteristics of Mononine. Acta Haernatologica 94, 25-32
51. Feldman, P. and Winkelman, L. (1991). Preparation of special plasma products. In: Blood separation and plasma fractionation. Ed, J. R. Harris, pp 341-383. New York: Wiley-Liss Inc
52. Feldman, P. A., Bradbury, P. I., Williams, J. D., Sims, G. E., Mcphee, J. W., Pinnell M A Harris, L Crombie, G. I. and Evans, D. R. (1994). Large scale preparation and biochemical characterisation of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography. Blood Coagulation and Fibrinolysis 5, 939-948
53. Fenton, J. W., Fasco, M. J. and Stackrow, A. B. (1977). Human thrombins. Production, evaluation, and properties of alpha-thrombin. Journal of Biological Chemistry 252, 3587-3598
54. Finlayson, J. S. (1979). Therapeutic plasma fractions and plasma fractionation: prologue. Seminars in Thrombosis and Hemostasis 6, l-11
55. Fletcher, M. L., Trowell, J. M., Craske, J., Pavier, K. and Rizza, C. R. (1983). Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. British Medical Journal of Clinical Research Edition 287, 1754-1757
56. Frjesen, A. D. (1987). Chromatographic methods of fractionation. Developments in Biological Standardization 67, 3-13
57. Fuhge, P., Heimburger, N., Stöh, R H. A. and Burk, W. (1987). Readily dissolvable lyophilised fibrinogen formulation (US Patent 4650678)
58. Fulcher, C. A. and Zimmerman, T. S. (1982). Characterisation of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proceedings of the National Academy of Sciences of the United States of America 79, 1648-1652
59. Gadek, J. E., Klein, H. G., Holland, P. V. and Crystal, R. G. (1981). Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. Journal of Clinical Investigation 68, 1158-1165
60. Gellis, S. S., Neefe, J. R., Stokes, J., Strong, L. E., Janeway, C. A. and Scatchard, G. (1948). Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. Journal of Clinical Investigation 27, 239-244
61. Gerety, R. J. and Aronson, D. L. (1982). Plasma derivatives and viral hepatitis. Transfusion 21 347-351
62. Gerritzen, A., Schneweis, K. E., Brackmann, H. H., Oldenberg, J., Hanfland, P., Gerlich, W. H. and Caspari, G. (1992). Acute hepatitis A in haemophiliacs. Lancet 340, 1231-1232
63. Glaser, C. B., Karic, L. and Fallat, R. (1975). Isolation and characterization of alpha-I-antitrypsin from the Cohn fraction IV-I of human plasma. Preparative Biochemistry 5 333-348
64. Gowda, S., Emery, E. and Kosow, D. (1994). The removal of hepatitis A virus (HAV) during the manufacture of Hemofil M, Antihemophilic Factor (Human), Method M, Monoclonal purified. Abstract 256. Presented at Annual meeting of American Society of Hematology, Tennessee, U. S. A
65. Grun, J. B., White, E. M. and Sito, A. F, (1992). Viral removal/inactivation by purification of biopharmaceuticals. BioPhanna 5, 22-30
66. Habeeb, A. F. S. A. and Francis, R. D. (1977). Immunoglobulin free of plasmin and anticomplement activities. Vox Sanguinis 32, 423-434
67. Hamamoto, Y., Harada, S., Kobayashi, S., Yamaguchi, K., Iijima, H., Manabe, S., Tsurumi, T., Aizawa, H. and Yamamoto, N. (1989). A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sanguinis 56, 230-236
68. Hamman, J., Zou, J. and Horowitz, B. (1994). Removal and Inactivation of hepatitis A Virus (HAV) during processing of Factor VIII concentrates. Vox Sanguinis 67, 72-77
69. Henin, Y., Marechal, V., Barre-Sinoussi, F., Chermann, J. C. and Morgenthaler, J. J. (1988). Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sanguinis 54, 78-83
70. Herring, S. W., Abildgaard, C., Shitanishi, K. T., Harrison, J., Gendler, S. and Heldëbrant, C. M. (1993). Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. Jotiniai of Laboratory and Clinical Medicine 121 394-405
71. Hilfenhaus, J. and Nowak, T. (1994). Inactivation of hepatitis A virus by pasteurization and el imination of picomaviruses during manufacture of Factor VIII concentrate. Vox Sansuinis 67, 62-66
72. Hjorth, R. and Moreno-Lopez, L. (1982). Purification Of Bovine Papilloma Virus By Gel Filtration On Sephacryl S-1000 superfine. Journal of Virological Methods 5, 151-158
73. Hoffer, L., Schwinn, H., Biesert, L. and Josic, D. (1995). Improved virus safety and purity of a chromatographicaily produced factor IX concentrate by nanofiltration. Journal of Chromatography - Biomedical Applications 669, 187-196
74. Hoffman, D. (1989). Purification and large scale preparation of antithrombin III. American Journal of Medicine 87 (3B), 23-26S
75. Hoppe, H. H., Mester, T., Hennig, W. and Krebs, H. -J. (1973). Prevention of Rh-Immunisation. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography. Vox Sanguinis 25, 308-316
76. Horowitz, B. and Piet, M. Pj. (1986). Transmission of viral diseases by plasma protein fractions. Plasma Therapy and Transfusion Technology 7, 503-513
77. Hwang, D. S., Nario, E., Lepe, M., Luz, L., Ito, H. and Takechi, K. (1998). Process for separating alpha-1-proteinase inhibitor from Cohn Fraction 1V-1+ 1V-4 paste. WO 98/ 00154
78. Jason, J., Holman, R. C., Dixon, G., Lawrence, D. N., Bozeman, L. H., Chorba, T. L., Tregillus, L. and Evatt, B. L. and Hemophilia/Aids Collaborative Study Group. (1986). Effects of exposure to factor concentrates containing donations from identified AIDS patients. A matched cohort study. Journal of the American Medical Association 256, 1758-1762
79. Jernberg, M., Ohlsson, E., Winge, S., Westman, L. and Eriksson, B. (1996). Removal of viruses from factor IX solutions by Vire solve 70 filtration. Proceedings of XXII International Congress of World Federation of Haemophilia, June 1996, Dublin, Ireland. Appendix 12
80. Johnston, A. (1991). Optimisation of ion-exchange chromatography of proteins using mathematical models. Ph, D. Thesis. Melbourne, Australia: Monash University
81. Johnston, A., Hattarki, M. and Uren, E. (1996). Validation of virus removal and/or inactivation capacity of the Cohn Fractionation Steps. Abstract at the Blood Safety and Screening Conference, Amsterdam 1996
82. Johnston, A., Uren, E. and Goss, N. H. (2000b). Vims removal and/or inactivation during the manufacture of immunoglobulin. (In preparation)
83. Josic, D., Schwinn, H., Stadler, M. and Strancar, A. (1994). Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography. Journal of Chromatography B 662, 181-190
84. Kaersgaard, P. (1996). Chromatographic Viral Removal. Presented at Blood Safety and Screening Conference, Amsterdam, June 1996. CHI
85. Kernoff, P. B., Lee, C. A., Karayiannïs, P. and Thomas, H. C. (1985). High risk of non-A, non-B hepatitis after first time exposure to volunteer or commercial clotting factor concentrates: Effects of prophylatic immune serum globulins. British Journal of Haematology 60, 469-479
86. Kim, H. C., Mcmillan, C. W., White, G. C., Bergman, G. E., Horton, M. W. and Saidi, P. (1991). Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 79 (3), 568-575
87. Kistler, P. and Nitschmann, H. (1962). Large scale production of human plasma fractions. Vox Sanguinis 7, 414-424
88. Knapp, M. J. and Colburn, P. A. (1990). Clinical uses of intravenous immunoglobulin. Clinical Pharmacy. Drug Review 9, 509-529
89. Koenderman, A. H. L., Ter Hart, H. G. J., Hakkennes, C. T., Muller, E. J., Brands, L., Van Duren, N., Hiemstra, H. and Over, J. (1993). Development and preclinical evaluation of a high purity factor IX concentrate (Faktor IX-HPF). In: Biotechnology of Plasma Proteins: Purification, clinical and biological applications. Eds, J. -F. Stoltz and C. Rivat. Colloque INSERM 227, 81-86
90. Krasilnikov, I.V., Aksenova, T.A. and Mchedlishvili, B.V. (1981). Purification and concentration of rabies virus by chromatography on chemically modified porous silicates. Acta Virologica 25, 205-212
91. Lane, R.S. (1983). Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 2, 974-975
92. Laurell, C.B., Dahlqvîst, I. and Persson, U. (1983). The use of thiol-disuiphide exchange chromatography for the automated isolation of alpha 1-antitrypsin and other plasma proteins with reactive thiol groups. Journal of Chromatography 278, 53-61
93. Lawrence, J.E. (1993). Affinity chromatography to remove viruses during preparation of plasma derivatives. In: Virological safety aspects of plasma derivatives. Developments in Biological Standardization 81, 191-197
94. Lebing, W.R., Lee, D.C., Alred, P.A. and Paul, H.I. (1999). Development of a production scale chromatographic process for the purification of human IgG. Presented at SPICA 1998, September, Strasburg, France
95. LEMON, S.M., MURPHY, P.C., SMITH, A., ZOU, J., HAMMON, J., ROBINSON, S., HOROWITZ, B.(1994). Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. Journal of Medical Virology 43, 44-49
96. Liebman, H.A., Limentani, S.A., Furie, B.C. and Furie, B. (1985). Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex. Proceedings of the National Academy of Sciences of the United States of America 82, 3879-3883
97. Löf, A.-L., Berntorp, E., Eriksson, B., Mattson, C., Svinhufvud, L., Winge, s. and ÖSTLIN, A. (1993). Characterisation of a highly purified factor IX concentrate. In: Biotechnology of Plasma Proteins: Purification, clinical and biological applications. Eds. J.-F. Stoltz and C. RivaL Colloque INSERM 227, 69-74
98. Louie, R.E., Galloway, C.J., Dumas, M.L., Wong, M.F. and Mitra, G. (1994). Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 22, 13-19
99. Lutsch, C., Gattel, p., Fanget, B., Véron, J.-L., Smith, K., Armand, J. and Grandgeorge, M. (1993). Immunoaffinity purified, solvent-detergent treated factor IX. In: Biotechnology of Plasma Proteins: Purification, clinical and biological applications. Eds. J.-F. StoJtz and Rivat. Colloque INSERM 227, 75-86
100. MANNUCCI, P.M. (1992). Outbreak of hepatitis A among Italian patients with hemophilia. Lancet 339, 819
101. Marrs, S. (1993). Large scale albumin fractionation by chromatography. In: Biotechnology of Plasma Proteins: Purification, clinical and biological applications. Eds. J.-F. Stoltz and C. Rivat. Colloque INSERM 227, 169-173
102. Matsunaga, Y. (1995). Evaluation of human parvovirus B19 DNA contamination of factor VIII products. Developments in Biological Standardization 88, 217
103. McCarthy, M. (1996). HAV linked to clotting factors in US. Lancet 347, 251
104. McIntosh, R. V., Hardy, J. and MacGregor, I. (1998). Process design, virus inactivation and product testing in a solvent/detergent treated, terminally dry heat treated Fibrin sealant. Presentation at the Conference Emerging Applications of Tissue Sealants, Lisbon. Portugal, November 1998. CHI
105. Michael, S.E. and Tunnah, G.W. (1966). The purification of factor 8 (antihaemophilic globulin). II. Further purification and some properties of factor 8. British Journal of Haematology 12, 115-132
106. Michalski, C., Burnouf, T, and Huart, J.J. (1993). Five years experience in the production and quality control of a highly purified factor IX concentrate. Biotechnology of Blood Proteins. Eds. J.-F. Stoltz and C. Rivat, pp 91-96. Colloque JNSERM/John Libbev Eurotext Ltd. Vol 227
107. Middleton, S.M., Bennett, I.H. and Smith, J.K. (1973). A therapeutic concentrate of coagulation factors II, IX and X from citrated factor VIII depleted plasma. Vox Scmguinis 24, 441-456
108. Miller-Andersson, M., Borg, H. and Andersson, L.-O. (1974). Purification of antithrombin III by affinity chromatography. Thrombosis Research 5, 439-452
109. Mitra, G., Dobkin, M., Dumas, M., Ng, P., Roldan, G. and Galloway, C. (1994). Hepatitis A viral safety of plasma derived factor VIII concentrate Koate-HP. Vox San guinis 67, 80-82
110. Modi, G. J., Blajchman, M. A. and Ofosu, F. A. (1984). The isolation of prothrombin, factor (1998). and factor X from human factor IX concentrates. Thrombosis Research 36, 537-547
111. Mohr, H., Lambrecht, B., Marks, F. and Tschech, A. (1994). Hepatitis A virus PCR analysis of clotting factor concentrates and elimination of non-enveloped viruses in their manufacture. Vox Sanguinis 67, 78-79
112. Morgenthaler, J. -J. (1989). Virus inactivation on plasma products. Curretu Studies in Hematology and Blood Transfusion 56, 109-121
113. Noinville, V., Craescu, C. T., Vidal-Madjar, C. and Sebille, B. (1995). Molecular approach to protein polymer interactions in ion-exchange chromatography. Journal of Chromatography B 664, 33-38
114. Nordenman, B. and Bjork, I. (1977). Purification of thrombin by affinity chromatography on immobiiised heparin. Thrombosis Research 11, 799-808
115. Oates, A., Kupczyk, M. and Kanellos, J. (1997). Method for purification of thrombin. WO 97/04081
116. Ochs, H. D., Fischer, S. H. and Virant, F. S. (1985). Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet i, 404-405
117. Oncley, J. L., Melin, M., Richert, D. A., Cameron, J. W. and Gross, P. M. (1949). The separation of antibodies, isoagglutinins, prothrombin, plasminogen and beta-1-lipoprotein into sub-fractions of human plasma. Journal of the American Chemical Society 71, 541-550
118. Pawlotsky, J. M., Bouvier, M., Duval, J., Bierling, P. and Dhumeaux, D. (1994). Chronic hepatitis C after high-dose intravenous immunoglobulin. Transfusion 34, 86-87
119. Peerlinck, K. and Vermylen, J. (1993). Acute hepatitis A in patients with haemophilia A. Lancet 341, 179-183
120. Peterson, E. A. and Sober, H. A. (1956). Chromatography of proteins. I. Cellulose ionexchange adsorbents. Journal of the American Chemical Society 78, 751-755
121. Porath, J. and Flodin, P. (1959). Gel filtration. A method for desalting and group separation. Nature 183, 1657-1659
122. Porath, J., Carlsson, J., Olsson, I. and Befrage, G. (1975). Metal chelate affinity chromatography, a new approach to protein fractionation. Nature 258, 598-599
123. Proba, Z., Brodniewicz, T., Dupuis, N. and Bui-Khac, T. (1996). Therapeutic grade thrombin production and products. WO 96/09376
124. Prowse, C. T., Ludlam, C. A. and Yap, P. L. (1997). Human parvovirus B19 and blood products. Vox Sanguinis 72, 1-10
125. Ristol, P., Gensana, M., Fernandez, J., Massot, M., Biescas, H., Darling, A., Jorquera, J. I. and Vericat, F. (1996). Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI). Sangre (Bare) 41, 131-136
126. Rtzza, C. R., Fletcher, M. L. and Kernoff, P. B. A. (1993). Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): A report on behalf of U. K. Haemophilia Centre Directors. British Journal of Haematology 84, 269-272
127. Roberts, P. L. (1995). Virological safety of the purified factor IX concentrate, Replenine. Haemophilia 1, 19-22
128. Roberts, P. L. (1996a). Vims safety of plasma products. Reviews in Medical Virologv 6, 2538
129. Roberts, P. L. (1996b). Removal of parvovirus and hepatitis A virus by metal chelate affinity chromatography during the preparation of Replenine: a high purity Factor IX concentrate. Vox Sanguinis 71, 129-130
130. Rock, G. (1991). Purification of Factor VIII procoagulant. In: Blood Separation and Plasma Fractionation, Edition 1. Ed, J. R. Harris, pp 241-259. New York: Wiley-Liss, Inc
131. Sadana, A. (1992). Protein adsorption and inactivation of surfaces. Influence of heterogeneities. Chemical Review 92, 1799-1818
132. Scaroni, C., Cancelueri, V., Carnelli, V., Moroni, G. A. and Angeli, M. (1980).Addition of hepatitis B immunoglobulins to clotting factors. Lancet 2, 537-538
133. Schreiber, A. B., Hrinda, M. E., Newman, J., Criss Tarr, G., D'Alisa, R. and Curry, W. M. (1989). Removal of viral contaminants by monoclonal antibody purification of plasma proteins. Current Studies in Hematology and Blood Transfusion 56, 146-153
134. Shields, P. A. and Farrah, S. R. (1983). influence of salts on electrostatic interactions between poliovirus and membrane filters. Applied and Environmental Microbiology 45, 526-531
135. Skidmore, S. J., Past, K. J., Mawson, S. J., Williams, M. D. and Hill, F. G. H. (1990), Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. Journal of Medical Virology 30, 50-52
136. Smith, K. (1988). Immunoaffinity purification of factor IX from commercial concentrates and infusion studies animals. Blood 72, 1269-1277
137. Smith, M. P., Rice, K. M. and Savidge, G. F. (1997). Successful clinical use of a plasmadenved, dual virus inactivated Factor VIII concentrate incorporating soivent-detergent and dry heat treatment Thrombosis and Haemostasis Letters 77, 403-407
138. Sofer, G. K. and Hagel, L. (1997). Handbook of process chromatography: A guide to optimization, scale up and validation. Eds, G. K. Sofer and L. Hagel, Chapters 5 and 8 U. S. A.: Academic Press
139. S Tender, S. and Kaesgaard, P. (1997). Clinical experience with Nordiate, a high purity double virus inactivated factor VII preparation. Presented at the XVIth ISTH Florence June 1997
140. Stoltz, J. -F., Rivat, C, Grandgeorge, M., Geschier, C., Sertillances, P., Venon, J. -L., Liautaud, J. and Dumont, L. (1993). Study of the virus inactivation or elimination capacity of a chromatographic procedure for purifying human plasma albumin. Biotechnobgy of Blood Proteins. Eds, C. Rivat and J. F. Stoltz. Colloque INSERM/John Libbev Eurotext Ltd. Vol 227, 267-272
141. Tanaka, K., Sawatani, E., Nakao, H. C., Dias, G. A. and Arashiro, F. (1998). An alternative column chromatographic process for the production of human albumin. Brazilian Journal of Medical and Biological Research 29, 185-191
142. Tayot, J. L., Tardy, Ml, Gattel, P., Cueille, G. and Liautaud, J. (1987). Large scale use of Spherosil ton exchangers in plasma fractionation. Developments in Biological Standardization 57, 15-24
143. Temperley, I. J., Cotter, K. P., Walsh, T. J., Power, J. and Hillary, I. B (1992). dotting factors and hepatitis A. Lancet 340, 1466
144. Thorell, L. and Blomback, B. (1984). Purification of Factor VIII complex. Thrombosis Research 35 (4), 431-450
145. Tousch, D., Allary, M., Saint-Blancard, J. and Boschetti, E. (1989). Preparative Purification of IgG from a Human Plasma Alcohol Precipitate. In: Biotechnology of Plasma Protein. Eds, J. F. Stoltz and C. Rivat. Colloque INSERM 175, 229-236
146. Travis, J. and Pannell, R. (1973). Selective removal of albumin from plasma by affinity chromatography. Clinica Chimica Acta 49, 49-52
147. Tse, D., Mankarious, S., Liu, S. -L., Thomas, W., Alpern, M., Enomoto, S. and Garanchon, C. M. (1995). Topical fibrinogen complex. WO 95/25748
148. Unger, K. K. (1990). Packings and stationary phases in chromatographic techniques. Chromatographic Science Series. New York: Marcel Dekker, Inc. 47, 43-85 and 331-720
149. Vsron, J. -L., Gattel, P., Pla, J., Fournier, P. and Grandgeorge, M. (1993). Combined Cohn/chromatography purification process for the manufacturing of high purity human albumin from plasma. Biotechnology of Blood Proteins. Eds C. Rivat and J. F. Stoltz. Colloque INSERM/John Libbey Eurotext Ltd. Vol 227, 183-188
150. Wickerhauser, M., Williams, C. and Mercer, J. (1979). Development of large scale 28 f 293t, 0n methods'VII-Preparation of anti thrombin III concentrate. Vox Sanguinis 36
151. Young, I. F., Mrcucci, V., Herrington, R. W., Turner, P. J. and Davies, J. R. (1999). Development of a process for the preparation of human serum albumin using chromatographic methods. Biotechnology of Blood Proteins 227, 143-149
152. Yei, S., Yu, M.W., and Tankersley, D. L. (1992). Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 32, 824-828
153. Zimmerman, T. S. (1988). Purification of Factor VIII by monoclonal immunoaffinity chomatography. In: Human Factor VIIIC: Purified using monoclonal antibody to Von Willebrand Factor. Seminar in Hematology 25, (Supp. 2(1)), 25-26